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Abstract 
Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies, 
leading to improved outcome. High-throughput technologies allow deepening into the molecular 
architecture of breast cancer, integrating different levels of information, which is important if it 
helps in making clinical decisions. MicroRNA and protein expression profiles were obtained from 
71 estrogen receptor-positive and 25 triple-negative breast cancer samples. RNA and proteins 
obtained from formalin-fixed, paraffin-embedded tumors were analyzed by RT-qPCR and LC-
MS/MS respectively. We applied probabilistic graphical models representing complex biological 
systems as networks, confirming that estrogen receptor-positive and triple-negative breast cancer 
subtypes are distinct biological entities. The integration of miRNA and protein expression data 
unravels molecular processes that can be related to differences in the genesis and clinical 
evolution of these types of breast cancer. Our results confirm that triple-negative breast cancer 
has a unique metabolic profile that may be exploited for therapeutic intervention.  
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Introduction 
Breast cancer is a major health issue in developed countries. Early diagnosis and the use of 
adjuvant therapies have contributed to improve survival, but still over 95,000 women are 
expected to die of breast cancer in the European Union in 2015 (1). In the last decades, the death 
rate from breast cancer has decreased gradually, due to early diagnosis and to the availability of 
adjuvant chemotherapy and hormonal therapy. Early diagnosis allows the detection of in situ or 
very small infiltrating tumors, which have an excellent prognosis, whereas adjuvant therapy 
decreases the rate of relapse. For this reasons, factors determining the use of such therapies are 
key elements in patient management. Knowledge on the molecular biology of breast cancer has 
recently challenged the way in which oncologists make decisions on adjuvant chemotherapy. A 
number of techniques, such as gene profiling, proteomics and microRNA analysis have been used 
to study this disease. 
Gene profiling in breast cancer has received increasing attention in recent years as a way to 
provide prognostic and predictive information. Since the description of a 70-gene profile in 2002 
by van’t Veer and colleagues, this and other gene signatures such as Recurrence Score have made 
their way into the clinic very rapidly, because they provide clinically useful information (2).  
Proteomics would enable the unbiased comparison of different cellular states in biology and 
medicine at a systems-wide level (3). Proteome analysis heavily relies on mass spectrometry (MS). 
MS-based proteomics is starting to mature and to deliver through a combination of developments 
in instrumentation, sample preparation and computational analysis. These advances allow the 
identification of thousands of proteins from tissue amounts compatible with clinical routine, which 
is relevant for the study of complex diseases. For example, thousands of mutations have been 
described associated with cancer (4), but the exact relationship between genomic variation and 
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the resulting phenotype in each individual tumor remains unknown. Deep proteomics analyses are 
necessary to characterize the complete scenario of signaling pathways and biological processes 
altered as a result of the specific mutation set produced in each tumor. 
MicroRNAs play an important role as regulators of gene expression, controlling many biological 
processes such as growth, development, differentiation and apoptosis. This has led to 
considerable interest in the development of miRNA expression profiles as a new class of 
biomarkers in cancer, cardiovascular and autoimmune diseases. Measuring miRNA expression can 
also be useful for systems-level studies of gene regulation, especially when miRNA measurements 
are combined with mRNA profiling and other genome-scale data (5). 
A major limitation for the widespread use of high-throughput techniques is tissue availability. 
Fresh or fresh-frozen specimens are ideal for molecular profiling but rarely available in the clinic. 
In recent years, we and others have demonstrated that formalin-fixed, paraffin embedded (FFPE) 
tissue can be readily analyzable by MS-based technologies (6, 7). On the other hand, previous 
studies demonstrate the possibility of performing experiments to analyze the expression of 
miRNAs (8) in FFPE tissues. FFPE samples also constitute the basis for routine workup in pathology 
departments all over the world. 
In this paper, we combined quantitative proteomics with miRNA expression analyses in a series of 
breast cancer samples with appropriate clinical information. We demonstrate that it is possible to 
perform differential protein expression analyses by LC-MS/MS on tens of FFPE tumors. Protein 
patterns confirm that estrogen receptor-positive (ER+) and triple-negative (TNBC) breast cancer 
subtypes are distinct biological entities (9). Also, we were able to profile miRNA expression in the 
same series of samples, which led us to conduct a probabilistic graphical models analysis to 
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integrate miRNA and protein expression data. This systems-level study sheds light on the 
molecular processes differentially regulated in these two main subtypes of breast cancer. 
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Materials & Methods 
Study design and sample description 
Our primary objectives were to develop a method for the study of both proteins and microRNA 
expression pattern from a systems biology point of view, and to identify differences in biological 
processes between the two main groups of breast cancer patients: estrogen receptor-positive, 
ER+, and triple-negative breast cancer, TNBC. One hundred and six FFPE samples from patients 
diagnosed of breast cancer were retrieved from I+12 Biobank (RD09/0076/00118) and from IdiPAZ 
Biobank (RD09/0076/00073), both integrated in the Spanish Hospital Biobank Network (RetBioH; 
www.redbiobancos.es). The histopathological features of each sample were reviewed by an 
experienced pathologist to confirm diagnosis and tumor content. Eligible samples had to include at 
least 50% of tumor cells. Approval from the Ethical Committees of Hospital Doce de Octubre and 
Hospital Universitario La Paz was obtained for the conduct of the study.  
 
Total protein preparation 
Proteins were extracted from FFPE samples as previously described (10). Briefly, FFPE sections 
were deparaffinized in xylene and washed twice with absolute ethanol. Protein extracts from FFPE 
samples were prepared in 2% SDS buffer using a protocol based on heat-induced antigen retrieval 
(6). Protein concentration was determined using the MicroBCA Protein Assay Kit (Pierce-Thermo 
Scientific). Protein extracts (10 µg) were digested with trypsin (1:50) and SDS was removed from 
digested lysates using Detergent Removal Spin Columns (Pierce). Peptide samples were further 
desalted using ZipTips (Millipore), dried, and resolubilized in 15 µL of a 0.1% formic acid and 3% 
acetonitrile solution before MS analysis. 
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Liquid chromatography - mass spectrometry analysis  
Samples (4 µL) were analyzed on a LTQ-Orbitrap Velos hybrid mass spectrometer (Thermo Fischer 
Scientific, Bremen, Germany) coupled to NanoLC-Ultra system (Eksigent Technologies, Dublin, CA, 
USA). Peptide separation was performed on a self-made column (75 µm × 150 mm) packed with 
Magic RP C18 AQ, 200A, 3 μm beads (Bischoff GmbH, Leonberg, Germany) at a flow rate of 
250nL/min. Solvent composition was 0.1% formic acid for channel A, and 0.1% formic acid and 
99.9% acetonitrile for channel B. The peptides were eluted with a gradient of 5 to 30% acetonitrile 
in 95 minutes. The mass spectrometer was operated in data-dependent mode (DDA), acquiring a 
full-scan MS spectra (300−1700 m/z) at a resolution of 30,000 at 400 m/z after accumulation to a 
target value of 1,000,000, followed by CID (collision-induced dissociation) fragmentation on the 
twenty most intense signals per cycle. CID spectra were acquired using normalized collision energy 
of 35 and a maximum injection time of 50 ms. The automatic gain control (AGC) was set to 10,000 
ions. Charge state screening was enabled and singly and unassigned charge states were rejected. 
Precursor masses previously selected for MS/MS measurement were excluded from further 
selection for 45 s, and the exclusion window was set at 10 ppm. The size of the exclusion list was 
set to a maximum of 500 entries. The samples were acquired using internal lock mass calibration 
on m/z 429.088735 and 445.120025. 
 
Label-free protein expression data processing 
The acquired raw MS data were processed by MaxQuant (version 1.2.7.4), followed by protein 
identification using the integrated Andromeda search engine. Spectra were searched against a 
UniProtKB/Swiss-Prot database for human (73,849 entries), including a set of and 260 common 
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protein contaminants (NCBI taxonomy ID 9606, download date 2011-12-13). Reversing the protein 
sequences was chosen as decoy option in MaxQuant. Carbamidomethylation of cysteine was set 
as fixed modification, while oxidation (M), deamidation (N, Q) and N-terminal protein acetylation 
were set as variable. Enzyme specificity was set to trypsin/P allowing a minimal peptide length of 7 
amino acids and a maximum of two missed-cleavages. Precursor tolerance was set to 20 ppm, 
while fragment was set to 0.5 Da. The maximum false discovery rate (FDR) was set to 0.01 for 
peptides and 0.05 for proteins. 
Label free quantification was performed setting a 2 minutes window for match between runs. The 
protein abundance was calculated on the basis of the normalized spectral protein intensity (LFQ 
intensity). Quantifiable proteins were defined as those detected in at least 75% of samples in at 
least one type of sample (either ER+ or TNBC samples) showing two or more unique peptides. Only 
quantifiable proteins were considered for subsequent analyses. Protein expression data were log2 
transformed and missing values were replaced using data imputation for label-free data using 
default values. Finally, protein expression values were z-score transformed. Batch effects were 
estimated and corrected using ComBat (11). 
All the mass spectrometry raw data files acquired in this study may be downloaded from Chorus 
(http://chorusproject.org) under the project name Breast Cancer Proteomics. The peptides output 
file from the MaxQuant analysis is provided as supplementary material. 
 
RNA extraction and MicroRNA expression 
Selected FFPE tumor specimens were cut into serial sections with a thickness of 10 µm. Total RNA 
was then isolated using the RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies). Purified 
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RNA quality control for quantity and purity was assessed using an ND-1000 NanoDrop 
spectrophotometer (Thermo Fisher Scientific). A preliminary analysis was performed to compare 
miRNA expression measurements between paired FF and FFPE samples, as described previously 
(12). MicroRNA expression profiling was performed using a custom TaqMan Array MicroRNA Card 
(Life Technologies) containing 95 FFPE-reliable assays, including four housekeeping miRNAs 
identified used NorMean (12), plus one mandatory control. RNA concentration was adjusted to 
166.7 ng/μL. For miRNA cDNA synthesis, 500 ng of total RNA was reverse-transcribed using the 
TaqMan MicroRNA Reverse Transcription Kit combined with the stem-loop Megaplex Primer Pools 
according to the manufacturer’s protocol (Life Technologies). All PCR reactions were performed on 
the ABI Prism 7900HT Sequence detection system (Life Technologies). Average cycling threshold 
(Cq) values were obtained using SDS 2.2 software (Applied Biosystems) employing automatic 
baseline settings and a threshold of 0.2. The maximum Cq value was set at 40. Cq values were 
normalized using two out of four reference miRNAs (hsa-let-7d and hsa-let-7g) selected as 
previously described (12). One microRNA was excluded from subsequent analyses because no 
detection was found in most of the samples. The relative expression level of each target gene was 
expressed as ΔCq = Cq ref-Cq gene. Cq ref was obtained calculating the geometric mean of two 
housekeeping miRs (let-7d and let-7g). Reference-normalized expression measurements were 
adjusted by defining the lowest expression value as 0, with subsequent 1-unit increases reflecting 
an approximate doubling of the RNA. Finally, values were z-scored. 
 
Assessing molecular differences between ER+ and TNBC samples 
Significance Analysis of Microarrays (SAM) was carried out to find differentially expressed proteins 
and miRNAs between ER+ and TNBC samples with a FDR below 5%. Hierarchical clusters were 
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constructed with the differentially expressed proteins or miRNAs between ER+ and TNBC samples 
identified by SAM, using Pearson Correlation and the average-linkage method.  Then, we used 
miRWalk (15th March 2013 version) (13) to find validated targets of these miRNAs among the 
proteins differentially expressed between ER+ and TNBC samples.  
 
Network construction 
Statistical analyses were conducted to associate miRNAs and proteins. As a first approach to 
describe associations present in our data base, we choose probabilistic graphical models 
compatible with high-dimensionality. The result is an undirected graphical model with local 
minimum Bayesian Information Criterion (BIC) (14) obtained after executing the next steps: first 
the spanning tree with maximum likelihood is found and then (I), a forward search is performed by 
successively adding edges that reduce the BIC and still preserve the decomposability (15) of the 
initial graph (II). In the first stage, which learns a Markov tree structure from a random sample of a 
supposed multidimensional normal population, we use the extension of the Chow-Liu solution 
(16), according to which, for categorical data, the maximum likelihood structure is given by the 
maximum weight spanning tree (17) with empirical mutual information quantities (18) as edge 
weights. In the Gaussian case, a similar reasoning applies, but now the mutual information value is 
–(1/2)log(1-r2), where r is the empirical correlation coefficient between the two variables (nodes) 
joined by the edge. Given that the algorithm is invariant under monotone transformations of the 
variables, r2 can be used as a weight. In the second phase, we introduce the BIC criterion which 
penalizes more complex models and then, simpler graphs are generated. This is a fundamental 
objective in high-dimensional problems. Both methods are implemented in the open-source 
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statistical programming language R (19). In particular, the functions minForest and stepw, in the 
gRapHD package (20), are used for phases I and II, respectively. 
 
Gene Ontology analyses 
Protein-to-gene ID conversion was performed using Uniprot (http://www.uniprot.org) and DAVID. 
Gene ontology analyses were performed using the functional annotation chart tool provided by 
DAVID. We used “homo sapiens” as background list and selected only GOTERM-FAT gene ontology 
categories and Biocarta, KEGG and Panther pathways.  
 
Functional node identification and activity measurement 
To identify functional nodes within the probabilistic graphical models, we split it in several 
branches. Then, we used gene ontology analyses to investigate which function or functions were 
overrepresented in each branch. To measure the functional activity of each node, we calculated 
the mean expression of all the proteins included in one branch related with a concrete function. 
Differences in node activity between ER+ and TNBC samples were assessed by class comparison 
analyses. 
 
Orthogonal verification 
We used published array expression data of 1,296 primary breast carcinomas from two previously 
published works (21, 22). Batch effects between data sets were estimated and corrected using 
ComBat (11). After protein-to-gene ID conversion, all probes in dataset for each gene were 
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retrieved. Probes with higher coefficient of variation were selected when multiple probes were 
found for a single gene. Differences in node activity between ER+ and TNBC samples were 
assessed using a two-sample T-test analysis comparing expression. A Multivariate Permutations 
test was computed based on 1000 random permutations, allowing a confidence level of false 
discovery rate assessment of 90 % and a maximum allowed proportion of false-positive genes of 
0.05 
 
Cell culture 
The ER+ cell lines MCF7 and T47D and the TNBC cell lines MDA-MB-231 and MDA-MB-468 were 
cultured in RPMI-1640 medium with phenol red (Gibco) supplemented with 10% heat-inactivated 
fetal bovine serum, 100 mg/mL penicillin and 100 mg/mL streptomycin. The TNBC cell line BT-20 
was cultured in Minimum Essential Medium supplemented with 10% heat-inactivated fetal bovine 
serum, 100 mg/mL penicillin and 100 mg/mL streptomycin. All cell lines were cultured at 37 ºC in a 
humidified atmosphere with 5% (v/v) CO2 in air. MCF7, T47D BT-20 and MDA-MB-231 cell lines 
were kindly provided by Dra. Nuria Vilaboa (Hospital Universitario La Paz, previously obtained 
from ATCC in January 2014). MDA-MB-468 cell line was obtained from ATCC (July 2014). Cell lines 
were routinely monitored in our laboratory and authenticated by morphology and growth 
characteristics, tested for Mycoplasma and frozen, and passaged for fewer than 6 months before 
experiments.   
 
Glucose and lactate measurements 
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250.000 cells were plated in 4 ml of fresh medium, and cultivated for 72h. Afterwards, 
supernatants were centrifuged to eliminate cellular debris. Lactate and glucose concentrations in 
cell supernatants and fresh media were measured on an amperometric electrode using the 
enzymes lactate oxidase and glucose oxidase respectively, in an ABL90 FLEX gas analyzer 
(Radiometer) with integrated gas, electrolyte, metabolite and CO-oximetry measurements. At 
least measurements from three different experiments are provided. Glucose consumption is the 
difference between glucose concentration in fresh medium and glucose concentration in cell 
supernatant after 72h of cell culture. Lactate production is the difference between lactate 
concentration in cell supernatant after 72h of cell culture and lactate concentration in fresh 
medium. Differences were assessed by Kruskall-Wallis test.  
 
Statistical analyses and software suites 
BRB-ArrayTools, SPSS v16software package, GraphPad Prism 5.1 and R v2.15.2 (with the Design 
software package 0.2.3) were used for all statistical analyses. All p-values were two-sided and 
p<0.05 was considered statistically significant. Expression data and network analyses were 
performed in MeV and Cytoscape software suites. BRB-ArrayTools has been developed by Dr. 
Richard Simon and BRB-ArrayTools Development Team. 
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Results 
Study goal and patient’s characteristics 
Our study aims to develop a method to study both proteins and microRNA expression pattern 
from a systems biology point of view, to discover differences in biological processes between the 
two main groups of breast cancer patients: estrogen receptor-positive, ER+, and triple-negative 
breast cancer, TNBC. One hundred and six patients were included in the study. Clinical 
characteristics from these patients are provided in table 1. All patients were node positive; all of 
them were negative when tested for Her2 amplification using immunohistochemistry and 
fluorescent in situ hybridization when needed; and all of them received adjuvant chemotherapy, 
(either anthracycline-based or not) plus hormonal therapy in the ER+ group.  
 
Protein extraction and MS analysis 
We have previously demonstrated that our workflow is high reproducible (10). One hundred and 
two FFPE samples yielded enough protein to perform the MS analyses (typically, more than 0.5 
milligrams of total protein was recovered from each sample). After MS workflow, 96 samples gave 
useful protein expression data (25 TNBCs and 71 ER+ tumors). A total of 3,239 protein groups were 
identified using Andromeda (Supplementary table 1), of which 1,095 presented at least two 
unique peptides and detectable expression in at least 75% of the samples in at least one type of 
sample (either ER+ or TNBC samples) (Supplementary table 2). No one decoy protein passed 
through these additional filters. Ten samples were excluded from the study; four of them did not 
yield enough protein to perform the MS analyses, and six did not reach the “mean minus twice the 
standard deviation”-threshold in the number of unique peptides identified. 
on May 9, 2016. © 2015 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 16, 2015; DOI: 10.1158/0008-5472.CAN-14-1937 
 
 
17 
 
 
Label-free proteomics analysis 
Label-free quantification was performed using MaxQuant (Supplementary table 1). Expression 
values for each protein were analyzed using Significance Analysis of Microarrays (SAM). We found 
100 protein differentially expressed between ER+ and TNBC samples with a FDR<5% 
(Supplementary table 3). Then, we built a hierarchical cluster using the expression values of these 
100 proteins (Figure 1). Gene ontology analyses from these 100 proteins showed a relevant 
enrichment in extracellular matrix proteins (Supplementary table 4). 
 
Orthogonal verification of differences between ER+ and TNBC samples 
We used previously published gene expression data as verification of the results obtained using 
SAM (21, 22). After protein-to-gene ID conversion, 90 out of 100 proteins could be matched by this 
method. We found that the differences identified at the protein level were confirmed for 74 
genes, which showed a significantly different expression in ER+ and ER- samples with a FDR<5%. A 
group of TNBC samples could not be defined in this verification series because HER2 status was 
not reported for most samples. 
 
MicroRNA expression analysis 
We analyzed the expression of 90 miRNAs in samples from the study with enough available tissue 
(Supplementary table 5 & 6). Expression values for each miRNA were analyzed using SAM. We 
found 19 miRNAs differentially expressed between ER+ and TNBC samples with an FDR<5% 
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(Supplementary table 7). miR-20a, miR-19a, miR-106a, miR-18a and miR-135b expression were 
higher in TNBC samples, whereas miR-190b, miR-375, miR-449a, miR-139-5p, miR-205, miR-342, 
miR-149, miR-625, miR-193b, miR-214, miR-125b, miR-199a-3p, miR-30a*and miR-30e* were 
more expressed in ER+ samples. Then, we built a hierarchical cluster using the expression values of 
these 19 miRNAs (Figure 2). As can be observed, TNBC samples cluster together. 
 
Systems Biology of breast cancers 
Both label-free protein quantification and microRNA expression data were available for 79 tumors 
(16 TNBC and 63 ER+ tumors). Once we identified proteins and miRNAs differentially expressed 
between ER+ and TNBC samples, we checked if any of these proteins had been previously 
described as a regulated target of any of these miRNAs using the validated targets module of 
miRWalk. We found that only five proteins were previously identified as targets of six miRNAs. This 
lack of information prompted us to explore new ways to generate relations, if not between 
miRNAs and proteins, between miRNAs and biological processes and pathways. 
Protein and microRNA expression data from all samples were used in the probabilistic graphical 
models analyses, with no other a priori information. Then, the resulting graph was processed 
(Figure 3) looking for a functional structure, i.e., if the proteins and miRNAs included in each 
branch of the tree had some relationship regarding their function. Thus, we divided our graph in 
twelve branches and a core, and performed gene ontology analyses. We isolate branches based on 
the structure of the probabilistic graphical model starting from the outside, with a minimum of 40 
proteins included in each branch to allow gene ontology analyses in each branch and the core 
independently. The structure of the probabilistic graphical model had a strong biological function 
basis, as ten out of twelve branches showed a significant enrichment in proteins related with one 
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or two specific biological functions (Figure 3). Gene ontology analyses also showed that the core 
includes proteins related with most of the categories identified in the branches, but no category 
was over-represented.   
The next step was to identify which functions are differentially represented between ER+ and 
TNBC tumors. To do this, we established the level of expression of each function node using the 
mean expression of all the proteins included in a given branch that belong to a single functional 
group, building twelve protein functional nodes (Figure 3 and Supplementary Table 8). Then we 
performed class comparison analyses to assess which functional nodes are differentially activated 
between ER+ and TNBC samples. Seven nodes showed significant differences between both 
groups. Metabolism B, Proliferation, Protein Synthesis and Mitochondria B functional nodes 
showed increased activity in TNBC samples, whereas Mitochondria A, Metabolism A and 
Extracellular Matrix nodes showed increased activity in ER+ tumors (Figure 4 and Supplementary 
Table 8).  
Then, we compared the proteins identified as differential between SAM and the probabilistic 
graphical model functional approach. Only twenty five proteins from the SAM analysis were also in 
the 239 proteins from the seven functional nodes differentially expressed between ER+ and 
TNBCs. Ultimately, we performed an orthogonal verification of the activity of these functional 
nodes in our validation dataset. Six out of seven nodes showed a significant difference of 
activation between ER+ and ER- samples. 
Regarding the miRNAs, our first observation was that most miRNAs were included in two big 
miRNA groups, meaning that relations at the expression level are stronger between these 
microRNAs themselves than the relation between microRNAs and proteins. One of these groups 
contains every measured miRNA from the human mir-17-92 cluster, whereas the other contains 
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more that 50% of all the miRNAs analyzed in this study (Figure 3). The most outstanding 
observation was that fifteen miRNAs were included in branches composed mainly by proteins 
(Supplementary Table 8).  
 
Function: Proliferation 
 
We found two different functions mixed in the same branch: Proliferation and Extracellular Matrix 
(ECM), and two miRNAs embedded within: miR-301a and miR-331-5p. Thirteen proteins related 
with regulation of cell proliferation belong to the proliferation node. STAT1 is more expressed in 
TNBC samples than in ER+ ones, whereas PURA expression is decreased in TNBC samples 
accordingly with SAM analyses. Measurement of the functional activity of this node showed a 
higher proliferation activity in our TNBC sample series (p<0.01), as well as in the validation cohort 
(p<0.001).  
 
Function: Extracellular matrix 
We also found 39 proteins related with ECM and focal adhesion. Eight of the components of this 
functional node were also found as differential between ER+ and TNBC samples in SAM analysis. 
All of them (Decorin, VCAN, Mimecan, Biglycan, COMP, Lumican, Prolargin and Asporin) showed 
lower expression in TNBC samples. Thus, it is not surprising that the ECM functional node activity 
highly differs between ER+ and TNBC samples, both in the proteomics analysis (p<0.01) and in the 
orthogonal validation (p<0.05).  
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Function: Metabolism 
We found two different branches related with metabolism, thus we evaluated these two 
functional metabolism nodes independently. Metabolism A functional node included 33 proteins. 
Among them, seven were identified as differentially expressed by SAM analyses. PHGDH, LDHB 
and P5CS (encoded by the ALDH18A1 gene) are more expressed in TNBC samples than in ER+, 
whereas DHPR, FBP1 and MCCB are decreased in TNBC samples. The functional activity of this 
node was higher in ER+ samples (p<0.01) and was also significant in the orthogonal validation 
(p<0.001). Three microRNAs were included in this functional node: miR-135b, miR-190b and miR-
224. Differential expression analysis showed that miR-135b expression was higher in TNBC 
samples, whereas miR-190b was less expressed in TNBC samples. Metabolism A includes proteins 
related with glutamine metabolism, such as P5CS, IDH1 and GLUD1. GLUD1 protein expression is 
slightly lower in TNBC tumors (fold change=0.66, p<0.05). 
Metabolism B functional node comprised thirteen proteins, including GAPDH, PGK1, HSP90, LDHA 
and Pyruvate kinase among others. When we measured the functional activity of this node, it 
appeared increased in TNBC both in our proteomics data (p<0.01) as in the orthogonal validation 
(p<0.001). However, only one protein (UPGA) was included among the 100 proteins identified as 
differentially expressed between ER+ and TNBC. Only one microRNA (miR-449a) was included in 
this functional node, and it was also detected by SAM as down-regulated in TNBC samples. So, we 
identified a functional node with increased activity and a miRNA related to it with decreased 
expression (Figure 4), showing a negative correlation (r=-0.45, p<0.001, r2= 0.20; Supplementary 
figure 1). Surprisingly, miR-449a expression was not significantly correlated to any of the thirteen 
proteins included in this functional node.  
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Function: Mitochondrial 
We found two different branches related with mitochondrial activity, thus we evaluated these 
functional mitochondrial nodes independently. Mitochondria A functional node included 37 
proteins. Among them, four were identified as differentially expressed by SAM analyses. CYBB is 
more expressed in TNBC than in ER+, whereas IVD, DCXR and HSD17B8 expression is decreased in 
TNBC samples. The functional activity of this node was higher in our ER+ samples (p<0.05), and 
was also confirmed by the orthogonal validation (p<0.001). Two microRNAs (miR-23b and miR-
375) were included in this functional node. miR-375 expression was also found increased in ER+ vs. 
TNBCs in SAM analysis. Mitochondria B functional node comprises 33 proteins, including, among 
others, Citrate synthase, SDHA and DLST, all related with the TCA cycle. Its activity is increased in 
TNBC samples in both our proteomics data (p<0.05) and in the orthogonal validation (p<0.001). 
None of the studied microRNAs were included in this functional node. Two proteins from this node 
showed an increased expression in TNBC samples in SAM analysis: ATP6V1D and SHMT2.  
 
Metabolic analyses in breast cancer cell lines 
We measured both the glucose consumption and lactate production in five breast cancer cell lines: 
two ER+ cell lines (MCF7 and T47D) and three TNBC cell lines (MDA-MB-231, BT-20 and MDA-MB-
468). TNBC cell lines showed higher glucose consumption than ER+ cell lines (Figure 5A). Lactate 
production was also higher in TNBC cell lines compared with ER+ ones (Figure 5B).      
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Discussion 
In this work we demonstrate that it is technically feasible to analyze up to a hundred of clinical 
samples by high-throughput proteomics, which could help to place mass spectrometry at the same 
level than gene microarrays, or massively parallel sequencing technologies, in its capability to 
analyze enough samples and features to generate clinically useful molecular profiles. Ongoing 
studies are trying to complete the molecular characterization of breast cancers (23). One key 
aspect of these studies is that they will analyze hundreds of samples to extract meaningful 
information, both from the medical and biological point of view. 
Our proteomics pipeline allowed us to detect 3,239 protein groups in FFPE breast tissues. We then 
applied stringent filters to avoid false detections and used only 1,095 proteins in subsequent 
analyses. It is remarkable that our label-free quantification approach can detect clinically relevant 
proteins such as HER2, STAT1 or PARP1. However, other clinically important markers such as ER, 
PR or KI67, were not detected using this technique. One obvious limitation of proteomics when 
compared to genomics is that genomics can measure the expression of all known genes in the 
same experiment, whereas proteomics only provides a measurement of peptides that are both 
detected and identified. This is directly related to the wide dynamic range of protein expression 
which means that the amount of some proteins can be orders of magnitude higher than others. 
Unfortunately, ER and PR are among these proteins showing low relative abundance in cells. We 
compared the abundance of ESR1, PRG and MKI67 with some proteins identified in our MS 
experiments using available data from PaxDB (24). ESR1 and PGR abundance is ten times lower 
than the less abundant protein identified in our MS experiments. Ki67 abundance is comparable to 
other detected proteins. We did not detect/identify any single peptide from this protein in our MS 
runs, thus with our experimental conditions, Ki67 cannot be detected in FFPE breast cancer 
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samples. These limitations could be overcome soon, as the latest developments in the field are 
promising. 
 
Label-free proteomics analysis 
SAM analysis identified one hundred proteins differentially expressed between ER+ and TNCB 
samples. Some of these proteins with higher expression in TNBC samples have been previously 
described as over-expressed in these tumors, such as PHGDH (25), LDHB (26), S100A8, S100A9 (27) 
and GRP78 (28), whereas AGR2, AGR3 (29), PIP (30) and GPD1 (31), have been shown to be up-
regulated in ER+ breast cancer tumors in concordance with our data. These results are strained by 
sample size. For this reason proteomic-based quantitation of potential biomarkers requires further 
validation using orthogonal techniques. It has been already demonstrated that mRNA levels largely 
reflect the respective protein levels (32). Consequently, the intersection between proteomic data 
sets and other genome-wide data sets often allows robust cross-validation. We used independent 
gene expression data from public datasets to corroborate our findings. It is remarkable that 74% of 
the differences observed in our proteomics data were confirmed using gene expression data, and 
are also consistent with previous reports. 
 
MicroRNA expression analysis 
Regarding microRNA differential expression analysis, miR-106a, miR-18a and miR-135b expression 
were higher in TNBC samples, whereas miR-190b, miR-375, miR-205, miR-342, miR-125b and miR-
214 were more expressed in ER+ samples. This is consistent with previously published data. miR-
342 expression has been beforehand described as significantly higher in ER+ samples, and was 
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included in a predictor of ER status together with miR-135b and miR-190 (33). Moreover, miR-342 
expression was positively correlated with ERα mRNA expression in human breast cancer (34). MiR-
205 was significantly under-expressed in triple-negative primary breast cancers when compared 
with tumor-associated normal samples. Both miR-205 and miR-342 have been proposed as 
potential biomarkers for diagnosis of TNBC (35). It has been previously showed that miR125b 
expression is lower in TNBC tumor tissue when compared with adjacent normal tissue, and has 
been related with chemoresistance (36).Finally, miR-345 expression was down-regulated in ER-
negative breast cancer patients, whereas miR-18a was increased (37).  
 
Systems Biology of breast cancers 
In this work, we have defined functional nodes and measured their activity, and also performed a 
comprehensive investigation of miRNA-mediated regulation through an integrative analysis of the 
variation of miRNA and protein expression in a large collection of breast cancer samples using a 
probabilistic graphical model approach. The relation among multiple types of molecules defines 
how they are regulated. Computationally linking and then analyzing these relations at the global 
scale could reveal entirely new levels of cell regulation and provide insights into damaged 
molecular pathways in disease (38). Integrated pathway analysis is expected to increase the 
precision and sensitivity of causal interpretations for large sets of observations since no single data 
source is likely to provide a complete picture by itself (39). 
This analysis identified twelve functional nodes, seven of which showed differential activation 
after a class comparison analysis when comparing ER+ and TNBC samples. Orthogonal validation 
using external gene expression datasets confirmed these differences in six out of seven nodes: 
ECM, proliferation, metabolism A & B and mitochondria A & B. Proliferation and ECM were 
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grouped in the same branch, despite that activity analyses showed that proliferation activity is 
increased in TNBC, whereas ECM is decreased. It is well known that TNBCs are highly proliferative 
tumors with high relapse rate, which is in concordance with our results. Probabilistic graphical 
model analyses showed that two microRNAs, miR-301a and miR-331-5p, are related with these 
functional nodes. It has been described that miR-301a promotes breast cancer proliferation, 
invasion, and tumor growth (40). It has also been described that miR-331 regulates SOCS1 (41), 
which acts as a negative feedback regulator of STAT (42). ECM node includes a number of proteins 
related with focal adhesion. There is a previous work showing differences in focal adhesion 
proteins between ER+ and ER- tumors measured using proteomics (43). 
Interestingly, the activity of all metabolism and mitochondria related nodes have a differential 
activity between ER+ and TNBC samples. Metabolism B and mitochondria B are increased in TNBC 
samples as compared with ER+ samples, whereas metabolism A and mitochondria A activity are 
decreased. On the other hand, high expression of LHDB has been associated with glycolytic 
phenotype (26), whereas it has been demonstrated that loss of FBP1 induces glycolysis and results 
in increased glucose uptake and macromolecule biosynthesis (44). Cancer cells reprogram their 
metabolism in order to satisfy their bioenergetics and biosynthetic requirements. The hallmark of 
tumor metabolism is aerobic glycolysis, or Warburg Effect, which was first described more than 80 
years ago (45). During recent years, interest in developing cancer metabolism inhibitors and the 
possibility of combining them with existing therapeutic approaches has increased dramatically, 
with academic and pharmaceutical groups actively pursuing this aspect of tumor physiology that 
could have profound anticancer effects and fundamentally change the treatment of cancer (46). 
All these results together (glycolysis and the TCA cycle showing differential activity, higher LDHB 
expression and lower FBP1 expression in TNBC), suggest that TNBC samples are highly glycolytic 
tumors, and confirm that TNBC have unique metabolic profiles that may be exploited for 
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therapeutic intervention (47).To support this hypothesis, we evaluated this differential metabolic 
profile in five breast cancer cell lines. TNBC cell lines showed higher glucose consumption and 
lactate production, as has been showed previously (26, 44, 47).  
Metabolism A node includes some proteins related with glutamine metabolism. Increased 
glutaminolysis has been described as a key feature of the metabolic changes in cancer cells 
compared to normal cells (48). Recent studies suggest differences in the metabolism of glutamine 
between ER− and ER + disease. It has been observed that ER- tumors have a shift in the 
equilibrium between glutamine and glutamate towards glutamate in the ER− disease (49, 50). We 
found that GLUD1 expression is slightly lower in TNBC tumors, which is consistent with previous 
reports describing that TNBCs have the lowest GLUD1 protein expression rate of all molecular 
subtypes, whereas HER2 positive tumors show the highest (51). We also detected a higher protein 
expression of P5CS in TNBC tumors.  P5SC is a mitochondrial enzyme that catalyzes the conversion 
of L-glutamate to P5C, a pivotal step in the biosynthesis of non-essential amino acids such as L-
proline, L-ornithine and L-arginine (52).  
While aerobic proliferating cells use glucose and glutamine for biomass production through the 
TCA cycle, hypoxic cells shunt glucose to lactate and rewire glutamine metabolism (53). GLUD1 
and other glutamate-consuming enzymes activity is stimulated under glucose deprivation 
conditions, while its activity is repressed during robust glycolysis (54). Glutamine can be used to 
drive the TCA cycle independently of glucose, contribute to lipid synthesis via IDH1, and be donor 
for the synthesis of non-essential amino acids -via transaminases and P5CS- and nucleotides (53, 
55). Further exploration of glutamine metabolic rewiring differences in subgroups of breast cancer 
is needed to validate our preliminary results. 
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It is remarkable that only one protein included in the Metabolism B node (UPGA) was included 
among the 100 proteins identified as differentially expressed between ER+ and TNBC. This result 
suggests that functional approaches can highlight differences in biological processes and pathways 
that cannot be unraveled through the analysis of individual genes or proteins. In this regard, both 
approaches complement each other.  
One of our main objectives was to find relations between microRNA and differential processes in 
two breast cancer subtypes. We observed that miR-449a expression was lower in TNBC samples, 
and our probabilistic graphical model analysis include it in the metabolism B node, showing a 
negative correlation with its activity, which is increased in TNBC samples. Surprisingly, no 
correlation between miR-449a expression and individual proteins from the node was found. Our 
results suggest that miR-449a absence is related with and increased glycolytic metabolism, and 
that miR449a exerts its regulatory effect over cellular metabolism indirectly, through regulation of 
yet unknown genes (Supplementary Figure 2). Low expression level of miR-449a was correlated 
with poor prognosis of lung cancer patients (56), but there are no studies about its role in breast 
cancer progression or its implication in the regulation of the metabolism. miR-449a deserves 
additional functional studies to investigate its relationship with metabolic rewiring in breast 
cancers, which is far beyond the scope of this work. 
High-throughput technologies are providing a comprehensive view of the molecular changes in 
cancer tissues. MS-based proteomics together with microRNA profiling allowed us to overview 
differential processes in ER+ and TNBC samples. However, there are still a number of 
improvements required before mass spectrometry based proteomics could be considered at the 
same level than genomics related technologies in terms of comprehensiveness and depth: 
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substantial advances in speed, sensitivity, reproducibility, better identification methods and 
standardization of protocols are still necessary.  
In conclusion, the integration of different levels of biological information can improve our 
knowledge of molecular processes in cancer cells. In this study we measured the expression of 
1,095 proteins and 90 miRNAs in breast cancer samples, unraveling differences in the activity of 
molecular processes, such as proliferation and metabolism, between ER+ and TNBC tumors that 
were also confirmed at the trascriptome level. Moreover, some miRNAs were shown to be related 
with these functional categories. These findings may provide a rational to design new treatments 
for TNBC.  
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Figures Legends 
Figure 1: Hierarchical cluster of proteins differentially expressed between ER+ (orange) and TNBC 
(pink) samples with an FDR<2% identified by Significance Analysis of Microarrays. Red means high 
expression and green low expression. Two main clusters of proteins can be observed, one up-
regulated (above) and other down-regulated (below) in TNBCs. Protein position in the cluster can 
be found in supplementary table 3. 
Figure 2: Hierarchical cluster of microRNAs differentially expressed between ER+ (orange) and 
TNBC (pink) samples with an FDR<5% identified by Significance Analysis of Microarrays. Red means 
high expression and green means low expression. Two main clusters of microRNAs can be 
observed, one up-regulated (above) and other down-regulated (below) in TNBCs.  
Figure 3: Probabilistic graphical model analysis unravel the functional organization of proteins and 
microRNAs in breast cancers. Branches with no functional structure and the core remain in gray, 
whereas colored branches harbor one or two functional nodes. Big gray circles correspond to 
microRNAs. 
Figure 4: Probabilistic graphical model showing median expression values of proteins and 
microRNAs in ER+ (A) and TNBC (B) samples. Red means high expression and green means low 
expression. The magnified area corresponds to the metabolism B node in ER+ (C) and TNBC (D). 
Big circles correspond to microRNAs. 
Figure 5: Metabolic activity of ER+ (white) and TNBC (gray) cell lines. A) Glucose consumption is 
measured in mg/dL. Kruskall-Wallis test indicates that differences between ER+ and TNBC cell lines 
are significant (p<0.05). B) Lactate production is measured in mmol/L. Kruskall-Wallis test indicates 
that differences between ER+ and TNBC cell lines are significant (p<0.01).  
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Table 1. Clinical characteristics of the patients included in the study. Clinical criteria are provided 
according to TNM classification. 
(http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page3).  Tumor 
grade is the description of a tumor based on how abnormal the tumor cells and the tumor tissue 
look under a microscope, for determination procedure, see 
http://www.cancer.gov/cancertopics/factsheet/detection/tumor-grade.  
 
 All ER+ TNBC 
Age at diagnosis (median) 54.6 (32-83) 54.2 (32-83) 61.2 (37-78) 
Age at diagnosis (mean) 55.2 54.1 58.5 
Tumor Size    
T1 33 (31%) 28 (35%) 5 (19%) 
T2 61 (58%) 42 (53%) 19 (73%) 
T3 10 (9%) 8 (10%) 2 (8%) 
T4 1 (1%) 1 (1%) 0 (0%) 
Multifocal 1 (1%) 1 (1%) 0 (0%) 
Tumor Grade    
G1 12 (11%) 12 (15%) 0 (0%) 
G2 33 (31%) 29 (36%) 4 (15%) 
G3 41 (39%) 21 (26%) 20 (77%) 
Unknown 20 (19%) 18 (23%) 2 (8%) 
Lymph node status    
N0 0 (0%) 0 (0%) 0 (0%) 
N1 71 (67%) 54 (68%) 17 (65%) 
N2 35 (33%) 26 (32%) 9 (35%) 
Chemotherapy    
No Anthraciclynes 34 (32%) 23 (29%) 11 (42%) 
Anthraciclynes 63 (59%) 51 (64%) 12 (46%) 
Anthraciclynes + taxanes 9 (9%) 6 (7%) 3 (12%) 
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